173 related articles for article (PubMed ID: 21738405)
1. Comparison of cell proliferation, protein, and glucose metabolism in musculoskeletal tumors in a PET study.
Tian M; Zhang H; Endo K
J Biomed Biotechnol; 2011; 2011():807929. PubMed ID: 21738405
[TBL] [Abstract][Full Text] [Related]
2. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography.
Yanagawa T; Watanabe H; Inoue T; Ahmed AR; Tomiyoshi K; Shinozaki T; Oriuchi N; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(2):175-82. PubMed ID: 12703009
[TBL] [Abstract][Full Text] [Related]
3. Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis.
Morita M; Higuchi T; Achmad A; Tokue A; Arisaka Y; Tsushima Y
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1672-81. PubMed ID: 24006150
[TBL] [Abstract][Full Text] [Related]
4. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
[TBL] [Abstract][Full Text] [Related]
7. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II.
Hamada K; Tomita Y; Qiu Y; Zhang B; Ueda T; Myoui A; Higuchi I; Yoshikawa H; Aozasa K; Hatazawa J
Ann Nucl Med; 2008 Oct; 22(8):699-705. PubMed ID: 18982473
[TBL] [Abstract][Full Text] [Related]
9. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 3T diffusion-weighted MRI and
Lee SY; Jee WH; Yoo IR; Jung JY; Im SA; Chung YG; Kang JH
Br J Radiol; 2019 Oct; 92(1102):20181051. PubMed ID: 31322913
[TBL] [Abstract][Full Text] [Related]
11. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma.
Kim M; Achmad A; Higuchi T; Arisaka Y; Yokoo H; Yokoo S; Tsushima Y
J Nucl Med; 2015 Jan; 56(1):16-21. PubMed ID: 25476535
[TBL] [Abstract][Full Text] [Related]
12. ¹⁸F-FAMT in patients with multiple myeloma: clinical utility compared to ¹⁸F-FDG.
Isoda A; Higuchi T; Nakano S; Arisaka Y; Kaira K; Kamio T; Mawatari M; Matsumoto M; Sawamura M; Tsushima Y
Ann Nucl Med; 2012 Dec; 26(10):811-6. PubMed ID: 22903817
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.
Nobusawa A; Kim M; Kaira K; Miyashita G; Negishi A; Oriuchi N; Higuchi T; Tsushima Y; Kanai Y; Yokoo S; Oyama T
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1692-700. PubMed ID: 23801167
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of ¹⁸F-α-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: comparison with ¹⁸F-FDG PET/CT and MRI.
Kim M; Higuchi T; Arisaka Y; Achmad A; Tokue A; Tominaga H; Miyashita G; Miyazaki H; Negishi A; Yokoo S; Tsushima Y
Ann Nucl Med; 2013 Jun; 27(5):423-30. PubMed ID: 23436243
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.
Khan N; Oriuchi N; Ninomiya H; Higuchi T; Kamada H; Endo K
Ann Nucl Med; 2004 Jul; 18(5):409-17. PubMed ID: 15462403
[TBL] [Abstract][Full Text] [Related]
16. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
17. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
18. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography imaging of musculoskeletal tumors in the shoulder girdle.
Suzuki H; Watanabe H; Shinozaki T; Yanagawa T; Suzuki R; Takagishi K
J Shoulder Elbow Surg; 2004; 13(6):635-47. PubMed ID: 15570232
[TBL] [Abstract][Full Text] [Related]
20. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
